Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cohort Analysis
100%
Glucose
93%
Diabetes
84%
Maturity Onset Diabetes of the Young
61%
Patient with Type 2 Diabetes
58%
COVID-19
50%
Randomized Controlled Trial
39%
Nonalcoholic Fatty Liver
35%
Propensity Score Matching
31%
Impaired Glucose Tolerance
30%
Titrimetry
29%
Insulin
26%
Liver Fibrosis
26%
Fibrosis
24%
Patient with Diabetes
22%
Hazard Ratio
21%
Heart Surgery
19%
Diabetes Mellitus
19%
Odds Ratio
18%
Continuous Glucose Monitor
18%
Hyperglycemia
17%
Blood Glucose
16%
Homeostatic Model Assessment
16%
Hemoglobin A1c
16%
Glomerular Filtration Rate
15%
Chronic Kidney Disease
15%
Cardiovascular Disease
15%
Coronary Artery Calcium
14%
Insulin Resistance
13%
Kidney Function
13%
Lipid
12%
Dipeptidyl Peptidase-4 Inhibitor
12%
Glycon
12%
Education
11%
Body Mass Index
11%
Physical Activity
11%
Fatty Liver
11%
Specific Mortality
11%
Mass Screening
10%
Treatment Group
10%
Creatinine
10%
Ultrafiltration
9%
Acromegaly
9%
Vertebra
9%
Resistance Index
9%
Transcatheter Arterial Chemoembolization
9%
Hepatocellular Carcinoma
9%
Coronary Computed Tomography Angiography
9%
Endocrinologist
9%
Proton-Pump Inhibitor
9%
Nursing and Health Professions
Continuous Glucose Monitoring
68%
Maturity Onset Diabetes of the Young
44%
Glucose
37%
Insulin
35%
Patient with Type 2 Diabetes
34%
Hemoglobin A1c
33%
Cohort Analysis
30%
Efficacy
22%
Impaired Glucose Tolerance
19%
Nonalcoholic Fatty Liver
19%
Titrimetry
19%
Education
18%
Glycemic Control
17%
Hyperglycemia
17%
Insulin Dependent Diabetes Mellitus
16%
Diabetes Mellitus
16%
Glucose Blood Level
14%
Accident Prevention
13%
Treatment Group
13%
Propensity Score
12%
Low Density Lipoprotein Cholesterol Level
12%
Lipid
11%
Self Care
11%
Continuous Glucose Monitoring System
9%
Fatty Liver
9%
Tertiary Care Center
9%
Thyroid Cancer
9%
Underweight
9%
End Stage Renal Disease
9%
Essential Hypertension
9%
Cardiovascular System
9%
Primary Hyperaldosteronism
9%
Patient with Type 1 Diabetes
9%
Chemoembolization
9%
Insulin Glargine
9%
Heart Surgery
9%
Home Care
9%
Liver Cell Carcinoma
9%
Food and Drug Administration
9%
Self Monitoring
9%
Hazard Ratio
9%
Confidence Interval
8%
Hypoglycemia
8%
Glucose Level
6%
Glycosylated Hemoglobin
6%
Acute Kidney Failure
6%
Bloodstream Infection
6%
Randomization
6%
Odds Ratio
5%
Body Mass
5%
Pharmacology, Toxicology and Pharmaceutical Science
Maturity Onset Diabetes of the Young
44%
Glucose
38%
Insulin
31%
Nonalcoholic Fatty Liver
30%
Palmitic Acid
30%
Cohort Study
20%
Dipeptidyl Peptidase IV Inhibitor
19%
sodium glucose cotransporter-2 inhibitors
19%
Sodium Glucose Cotransporter 2 Inhibitor
17%
Sodium Glucose Cotransporter
16%
Dulaglutide
16%
Randomized Controlled Trial
12%
Small Interfering RNA
11%
Diabetes Mellitus
11%
Fatty Liver
11%
Chronic Kidney Failure
11%
Protein Kinase B
11%
Diseases
9%
Coronavirinae
9%
Lipotoxicity
9%
Clusterin
9%
G Protein Coupled Receptor 120
9%
Sodium Glucose Cotransporter 2
9%
Glucagon Like Peptide Receptor Agonist
9%
All Cause Mortality
9%
Cancer Mortality
9%
Low Density Lipoprotein Cholesterol
9%
End Stage Renal Disease
9%
Disease Exacerbation
9%
Insulin Dependent Diabetes Mellitus
9%
Mammalian Target of Rapamycin
9%
Cytokine
9%
Docosahexaenoic Acid
9%
Angiotensin II
9%
Hemoglobin A1c
8%
Lipid
7%
Liraglutide
6%
Exendin 4
6%
Phosphotransferase
6%
Fatty Acid
5%
Placebo
5%
Hypoglycemia
5%
